A history of the Epstein-Barr virus (EBV) appears to alter the immune systems of people with specific genetic traits, causing their own cells to mistakenly flag brain proteins as dangerous threats, according to a new study. This discovery offers insight into how these risk factors…
Tweet Thomas et al. Anoctamin-2-specific T cells link Epstein-Barrvirus to multiple sclerosis. Cell (2026), https://doi.org/10.1016/j.cell.2025.12.032 Epstein-Barr virus (EBV) infection constitutes a prerequisite for multiple sclerosis (MS) development, and cross-reactivity between EBV nuclear antigen 1 (EBNA1) and anoctamin-2 (ANO2) antibodies was previously demonstrated in persons with…
A greater intake of vitamin D, from both food and supplements, was linked to a 42% lower risk of developing multiple sclerosis (MS) among women living in Norway, according to a large prospective study. “Our findings suggest that a higher dietary intake of vitamin D…
For a long time, food was simply a necessity — something I grabbed between classes, appointments, or bouts of fatigue. I didn’t think much about how it made me feel, aside from the noticeable energy dips or sugar highs. Living with multiple sclerosis (MS) has…
Throughout 2025, the team at Multiple Sclerosis News Today brought readers the latest advances and updates in research related to multiple sclerosis (MS). Here are the top 10 most-read news stories MSNT published this year. Source: irelandms.com
By Angel Blair I always considered myself a planner. I constantly made lists; I carefully thought out decisions, big or small, to get to the most optimal outcome. I loved comparing the pros and cons of possibilities for things to … Continue reading → Source:…
Find Therapeutics has secured CA$10 million (approximately $7.4 million) in funding to continue advancing tasronetide, its lead candidate for boosting myelin repair in people with multiple sclerosis (MS). The Series A extension financing round follows the completion of a Phase 1 trial in healthy volunteers,…
Tweet Six trials to Watch. Four for BTKi, CD40-CD40L and CD19 and here they are sold as inhibitors of progressive disease, but in reality they are all B cell inhibitors. BTKi may not be B cell depleters and so far two have been abit not…
People with multiple sclerosis (MS) who have mild disability still experience several disease-related difficulties at work — challenges that can lead employees to shift to part-time or possibly quit their jobs — even after their condition is disclosed, a new study in Norway highlights. In…
There are many times when the memories from the past can blind us from where we are going in life. It is only natural for all humans to hold a grudge and not know the best way to release those emotions. Often, we let our…